- Home
- GGZ vs COYA Comparison
GGZ vs COYA Comparison
Compare GGZ & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGZ
- COYA
- Stock Information
- Founded
- GGZ 2013
- COYA 2020
- Country
- GGZ United States
- COYA United States
- Employees
- GGZ N/A
- COYA N/A
- Industry
- GGZ Investment Managers
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- GGZ Finance
- COYA Health Care
- Exchange
- GGZ Nasdaq
- COYA Nasdaq
- Market Cap
- GGZ 105.1M
- COYA 99.8M
- IPO Year
- GGZ N/A
- COYA 2022
- Fundamental
- Price
- GGZ $12.62
- COYA $5.51
- Analyst Decision
- GGZ
- COYA Strong Buy
- Analyst Count
- GGZ 0
- COYA 4
- Target Price
- GGZ N/A
- COYA $17.00
- AVG Volume (30 Days)
- GGZ 12.8K
- COYA 41.5K
- Earning Date
- GGZ 01-01-0001
- COYA 08-11-2025
- Dividend Yield
- GGZ 5.39%
- COYA N/A
- EPS Growth
- GGZ N/A
- COYA N/A
- EPS
- GGZ 1.75
- COYA N/A
- Revenue
- GGZ N/A
- COYA $3,685,107.00
- Revenue This Year
- GGZ N/A
- COYA $105.26
- Revenue Next Year
- GGZ N/A
- COYA N/A
- P/E Ratio
- GGZ $6.79
- COYA N/A
- Revenue Growth
- GGZ N/A
- COYA N/A
- 52 Week Low
- GGZ $9.43
- COYA $4.65
- 52 Week High
- GGZ $12.50
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- GGZ 53.61
- COYA 45.71
- Support Level
- GGZ $12.80
- COYA $5.30
- Resistance Level
- GGZ $13.16
- COYA $5.87
- Average True Range (ATR)
- GGZ 0.22
- COYA 0.38
- MACD
- GGZ -0.06
- COYA -0.01
- Stochastic Oscillator
- GGZ 27.59
- COYA 33.96
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.